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Abstract
Background: Safety and effectiveness of efficacious antiretroviral (ARV) regimens beyond single-dose nevirapine
(sdNVP) for prevention of mother-to-child transmission (PMTCT) have been demonstrated in well-controlled
clinical studies or in secondary- and tertiary-level facilities in developing countries. This paper reports on
implementation of and factors associated with efficacious ARV regimens among HIV-positive pregnant women
attending antenatal clinics in primary health centers (PHCs) in Zambia.
Methods: Blood sample taken for CD4 cell count, availability of CD4 count results, type of ARV prophylaxis for
mothers, and additional PMTCT service data were collected for HIV-positive pregnant women and newborns
who attended 60 PHCs between April 2007 and March 2008.
Results: Of 14,815 HIV-positive pregnant women registered in the 60 PHCs, 2,528 (17.1%) had their CD4 cells
counted; of those, 1,680 (66.5%) had CD4 count results available at PHCs; of those, 796 (47.4%) had CD4 count
≤ 350 cells/mm3 and thus were eligible for combination antiretroviral treatment (cART); and of those, 581 (73.0%)
were initiated on cART. The proportion of HIV-positive pregnant women whose blood sample was collected for
CD4 cell count was positively associated with (1) blood-draw for CD4 count occurring on the same day as
determination of HIV-positive status; (2) CD4 results sent back to the health facilities within seven days; (3)
facilities without providers trained to offer ART; and (4) urban location of PHC. Initiation of cART among HIV-
positive pregnant women was associated with the PHC's capacity to provide care and antiretroviral treatment
services. Overall, of the 14,815 HIV-positive pregnant women registered, 10,015 were initiated on any type of
ARV regimen: 581 on cART, 3,041 on short course double ARV regimen, and 6,393 on sdNVP.
Conclusion: Efficacious ARV regimens beyond sdNVP can be implemented in resource-constrained PHCs. The
majority (73.0%) of women identified eligible for ART were initiated on cART; however, a minority (11.3%) of
HIV-positive pregnant women were assessed for CD4 count and had their test results available. Factors
associated with implementation of more efficacious ARV regimens include timing of blood-draw for CD4 count
and capacity to initiate cART onsite where PMTCT services were being offered.
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Background
Progress made in knowledge of HIV infection, and more
particularly in the use of antiretrovirals (ARVs), has
resulted in considerably reducing mother-to-child trans-
mission (MTCT) risk. Despite the increased availability of
ARVs, an unacceptably high number of infants are being
infected with HIV every year. In 2007 alone, 370,000 chil-
dren were infected worldwide, 90% of them through
MTCT and the majority in developing countries. [1]
The World Health Organization (WHO) recommends use
of efficacious ARV regimens beyond single dose nevirap-
ine (sdNVP). [2] HIV-positive pregnant women eligible
for antiretroviral treatment (ART) should be put on com-
bination antiretroviral treatment (cART), and those not
eligible should be given a short course ARV prophylaxis.
Single-dose nevirapine only is given to those identified
late in pregnancy or when the first two options are not fea-
sible. WHO also recommends that all HIV-exposed
infants be given an appropriate ARV prophylaxis.
The cornerstone in implementing efficacious ARV regi-
mens is identification of HIV-positive pregnant women in
need of cART for their own health. [2,3] In addition to
clinical staging, eligibility for cART is based on absolute
CD4 cell count, which is often limited to secondary or ter-
tiarylevel hospitals with capacity for immunological
screening. The majority of pregnant women in resource-
limited settings seek antenatal and delivery care from
midwives and nurses, most often in primary health cent-
ers (PHCs). These facilities have limited capacity to per-
form CD4 count and identify women in need of cART,
making implementation of efficacious ARV regimens a
challenge. [4,5]
In developing countries, safety and effectiveness of effica-
cious ARV regimens have been demonstrated in well-con-
trolled clinical studies or in secondary and tertiary level
facilities. [6-10] However, large-scale implementation in
PHCs in developing countries has not been widely
described. The objective of this review is to determine the
uptake of and factors associated with implementation of
more efficacious ARV regimens (beyond sdNVP) for pre-
vention of mother-to-child transmission of HIV (PMTCT)
among HIV-positive pregnant women in PHCs.
Context
Zambia is a developing country in sub-Saharan Africa
with an adult HIV prevalence rate of 15.2%. [11] In 2007,
an estimated 95,000 Zambian children under age 15 were
living with HIV. [11] Over 90% of pregnant women in
Zambia seek antenatal care. [4,5]
Zambia has been implementing PMTCT programs since
1999 with support of several donors, including the
USAID-funded Zambia Prevention, Care, and Treatment
Partnership (ZPCT). ZPCT, a partnership between Family
Health International (FHI) and the government of Zam-
bia, is supporting the Ministry of Health (MoH) to
strengthen and expand existing HIV/AIDS services in five
provinces: Northern, Luapula, Copperbelt, Central, and
North-Western. ZPCT implements activities within gov-
ernment health facilities at primary through tertiary levels.
A typical ZPCT-supported PHC has no doctor and usually
operates with a nurse. It may also have a clinical officer
and a laboratory technician. PHCs with laboratory facili-
ties usually offer basic laboratory services including full
blood count, HIV testing, syphilis testing, and blood film
for malaria. CD4 cell enumeration is normally under-
taken through a laboratory network, whereby blood sam-
ples from HIV-positive patients seen in PHCs are referred
to larger health facilities for full blood count, including
CD4 cell count, using the FACScount flow cytometer (Bec-
ton Dickinson, San Jose, California, USA). Per national
guidelines, all pregnant women that test HIV-positive
should have a CD4 cell enumeration. Blood samples of
HIV-positive pregnant women are collected either the
same day or another day usually within a week of the
clinic visit, based on availability of transportation for
samples. Transporting samples to the referral lab and
returning results to PHCs are coordinated by a laboratory
technician. One referral lab serves an average of 5 to 10
PHCs. Turnaround time for CD4 count results to be
returned to PHCs is 7 to 30 days.
The Zambian National Guidelines for PMTCT, updated in
2007, promote the use of efficacious ARV regimens at all
health facilities, including PHCs. [12] Women eligible for
cART are those with absolute CD4 count ≤ 350 cells/mm3
(regardless of clinical stage) and women in WHO clinical
stage 4 (irrespective of absolute CD4 count). Interpreta-
tion of CD4 count and initiation of cART occurs in one of
three ways: (1) at a PMTCT site by a PMTCT provider, (2)
at a PMTCT site by a mobile ART clinic team, or (3) at an
ART site following referral by a PMTCT provider. In the
standard PMTCT package, women are encouraged to
deliver at health facilities. They are offered infant feeding
counseling, family planning counseling, and referral for
comprehensive HIV clinical care, including cART if indi-
cated.
Methods
Data Collection and Analysis
This review is based on service data between April 2007
and March 2008 from all 60 PHCs supported by ZPCT, 24
in rural and 36 in urban areas in five provinces (Central,
Copperbelt, Luapula, Northern and North-Western), with
a total catchment population of 1,451,260. Aggregated
quarterly data by site were collected on number of: 1)BMC Public Health 2009, 9:314 http://www.biomedcentral.com/1471-2458/9/314
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HIV-positive pregnant women, 2) HIV-positive pregnant
women assessed for CD4 count, 3) HIV-positive pregnant
women with CD4 cell count available at PHC, 4) HIV-
positive pregnant women initiated on cART, 5) HIV-posi-
tive pregnant women initiated on short course ARV, 6)
HIV-positive pregnant women given sdNVP, and 7)
exposed infants who received an ARV prophylaxis.
Additional data collected by site included availability of
same-day blood collection for CD4 count enumeration,
number of days for return of CD4 count results, whether
ART-trained staff are on site, and place of initiation of
cART (on or off PMTCT site), and location of the PHC
(urban or rural).
Data were extracted from MoH-mandated PMTCT log-
books in PHCs. A workshop with ZPCT staff from the five
provinces was conducted to develop tools to aggregate
data from the logbooks. When finalizing the data collec-
tion tools, staff suggested that a page be added to the tools
to capture any additional comments that PMTCT service
providers wished to share.
Data analysis was performed using Epi Info 3.3.2 for Win-
dows and Stata SE Version 9.0 (College Station, TX). Chi-
squares with 95% confidence intervals were used to com-
pare proportions of uptakes among the following inde-
pendent variables: (1) sites providing same-day blood
draw for CD4 count enumeration compared to those pro-
viding blood draw in a subsequent visit, (2) sites provid-
ing CD4 count results within seven days compared to
those providing results in eight or more days, (3) sites
with ART-trained staff compared to sites without, and (4)
urban versus rural location of PHC. Multivariate regres-
sion was used to analyze the association between the
dependent variable as measured in proportions of HIV-
positive pregnant women assessed for CD4 count, and
independent variables listed above. Chi-squares with 95%
confidence intervals were also used to compare uptakes
between the first quarter (April to June 2007) and fourth
quarter (January to March 2008).
Ethical considerations
The review was submitted to FHI's Protection of Human
Subjects Committee and received exemption as it exam-
ined routinely collected, aggregated program data.
Results
Overall uptake of CD4 count assessment and cART 
initiation
Between April 2007 and March 2008, 14,815 HIV-positive
pregnant women were registered in the 60 PHCs. Of those
women, 2,528 (17.1%) had their blood sample collected
for CD4 count assessment; of those, 1,680 (66.5%) had
CD4 count results available at PHCs; of those, 796
(47.4%) had CD4 count ≤ 350 cells/mm3 and thus were
eligible for cART; and of those, 581 (73.0%) were initiated
on cART (Figure 1). Among available CD4 count results,
the median CD4 count was 366 cells/mm3, a finding con-
sistent with other studies in similar resource-limited con-
texts. [7,13,14]
Uptake of CD4 count assesment and cART initiation over 
time
Across the 12 months of observation, there was an
increase in the proportion of HIV-positive pregnant
women assessed for CD4 count, the proportion of CD4
count results available at PHCs, and the proportion of
HIV-positive women eligible for treatment who initiated
cART (Figure 2). During the first quarter, 12.2% of HIV-
positive pregnant women (95% confidence interval [CI],
11.2%13.2%) were checked for CD4 count; during the
fourth quarter, 24.5% (95% CI, 23.1%25.9%) were
assessed (p < 0.001). Similarly, during the first quarter,
the CD4 count results of 7.2% of HIV-positive pregnant
women (95% CI, 6.5%8.0%) were available at clinics
compared to 16.8% (95% CI, 15.6%18.1%) during the
fourth quarter (p < 0.001). Lastly, during the first quarter,
2.6% of all HIV-positive pregnant women (95% CI,
2.1%3.1%) received cART compared to 5.5% (95% CI,
4.8%6.3%) during the fourth quarter (p < 0.001).
a For all %, the denominator used the total number of
pregnant women tested HIV+ for each corresponding
period
Factors associated with uptake of CD4 count assessment 
and cART initiation
The uptake of CD4 cell enumeration among HIV-positive
pregnant women was positively associated with several
health system factors: (1) blood-draw for CD4 count
occurring on the same day as determination of HIV-posi-
tive status, (2) CD4 count results sent back to the health
facilities within seven days, (3) facilities without providers
trained to offer ART, and (4) health facility being located
in an urban area (Table 1). The result of the multivariate
regression analysis showed that same-day blood sample
for CD4 count and urban location of a PHC are positively
associated (results not shown, p < 0.001) with the propor-
tion of women assessed for CD4, after accounting for the
effects of the two other variables (CD4 count results avail-
able within seven days and facilities without trained ART
providers).
Data supported the association between initiation of cART
among HIV-positive pregnant women with the capacity of
PHCs to provide HIV/AIDS care and treatment services on
site (Table 1). A higher proportion of women seen at
PMTCT sites with the capacity to provide HIV/AIDS care
and treatment were initiated on cART relative to thoseBMC Public Health 2009, 9:314 http://www.biomedcentral.com/1471-2458/9/314
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seen at PMTCT sites without HIV/AIDS care and treatment
capacity. Of the 326 women seen in PMTCT sites with
capacity to provide HIV/AIDS care and treatment, 319 or
97.9% (95% CI, 96.3%99.4%) were initiated on cART,
while of the 470 eligible women seen in PMTCT sites
without HIV/AIDS care and ART capacity, 262 or 55.7%
(95% CI, 51.2%60.2%) were initiated on cART (p <
0.001).
Uptake of ARV regimens over time
Of the 14,815 HIV-positive pregnant women registered,
10,015 (67.6%) were initiated on any type of ARV regi-
men: 581 on cART, 3,041 on short-course, double-ARV
regimen, and 6,393 on sdNVP only (Figure 1). Also, 3,463
infants (23.4% of all HIV-exposed newborns) were initi-
ated on ARV prophylaxis.
The uptake of any ARV regimen among HIV-positive preg-
nant women increased over time: 48.8% (95% CI,
47.3%50.2%) of HIV-positive pregnant women were
being initiated on any ARV regimen during the first quar-
ter compared to 77.9% (95% CI, 76.6%79.3%) during the
fourth quarter (p < 0.001). Though the sdNVP-only regi-
men was used most frequently, its use decreased from
67.2% to 59.7% between the first and fourth quarters. The
use of AZT+sdNVP and cART regimens increased from
27.5% to 33.2% and 5.3% to 7.1% between the first and
fourth quarters, respectively (Figure 3). The uptake of ARV
prophylaxis among HIV-exposed children remained near
23% across the period of observation.
Discussion
This review demonstrated that implementation of effica-
cious ARV regimens for PMTCT is possible in PHCs in
resource-constrained settings. However, it also high-
lighted three key bottlenecks in implementing efficacious
ARV regimens: (1) capacity to assess CD4 count, (2) avail-
ability of CD4 count results at clinics, and (3) capacity to
initiate cART.
Most worrisome if the fact that nearly 83% of HIV-posi-
tive pregnant women did not have their blood collected
for CD4 cell enumeration. This major gap can be
explained by the non-systematization of same-day blood
Attrition cascade in implementing efficacious ARV regimens in PHC Figure 1
Attrition cascade in implementing efficacious ARV regimens in PHC.
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collection for CD4 count along with other probable
causes found in providers' comments such as (1) limited
sensitization for beneficiaries and providers on the impor-
tance of efficacious ARV regimens, and (2) a client flow
that continues to adjust to this relatively new interven-
tion. Other comments of PMTCT providers suggest that
stigma may prevent women from providing a blood sam-
ple for CD4 cell enumeration in an HIV/AIDS care and
treatment setting. Pregnant women, when determined to
be HIV-positive, may be reluctant to be seen in the same
waiting area with HIV/AIDS patients. In PHCs providing
ART on site, there is usually a separate structure and/or
waiting area specific to HIV/AIDS services. On the other
hand, at PHCs that do not provide ART onsite, women
provide blood samples in the antenatal setting of PHCs
and are therefore more likely to provide a sample (Table
1).
CD4 count uptake, availability of results at clinics, and cART initiation over time Figure 2
CD4 count uptake, availability of results at clinics, and cART initiation over time.
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Table 1: Percentage of women checked for CD4 count by type of PHC
In PHCs WITH same day blood-draw for CD4 check
(n = 6,830)
In PHCs WITHOUT same day blood-draw for CD4 check?
(n = 7,985)
P < 0.001
18.4% [95% CI, 17.5%  19.3%] 15.9% [95% CI, 15.1%  16.7%]
In PHCs where CD4 results are back WITHIN 7 days
(n = 12,499)
In PHCs where CD4 results are back MORE THAN 7 days 
after
(n = 2,316)
P = 0.003
17.5% [95% CI, 16.8%  18.1%] 14.9% [95% CI, 13.5%  16.4%]
In PHCs WITH onsite initiation of ART
(n = 5,985)
In PHC WITHOUT onsite initiation of ART
(n = 8,830)
P < 0.001
13.7% [95% CI, 12.9%  14.6%] 19.3% [95% CI, 18.5%  20.1%]
In PHCs located in urban areas
(n = 10,252)
In PHC located in rural areas
(n = 4,563)
P < 0.001
21.4% [95% CI, 20.7%  22.2%] 7.2% [95% CI, 6.5%  8.0%]BMC Public Health 2009, 9:314 http://www.biomedcentral.com/1471-2458/9/314
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The second major bottleneck was the receipt of CD4 count
results by PHCs. Test results of 33.5% of blood samples
collected for CD4 cell enumeration were never returned to
the clinic (Figure 1). Possible reasons mentioned in the
one-page comment form include a lack of coordination of
identification numbers between PHCs and laboratories,
limited efficiency of the sample referral network, frequent
breakdown of CD4 count machines, insufficient number
of trained laboratory technicians to run CD4 count labo-
ratory equipment, lab fees applied in some facilities for
CD4 count, and clerical errors.
The third bottleneck was observed at initiation of cART.
We found that 27% of women determined to be eligible
did not initiate treatment (Figure 1). Barriers suggested in
the comments from providers include the limited capacity
of PHCs to offer HIV/AIDS care and treatment onsite and
lack of training and sensitization among healthcare pro-
viders on implementation of a more efficacious ARV regi-
men.
Among HIV-positive women whose CD4 count results
were available, 47% were eligible for cART. When that per-
centage (47%) is applied to the 13,135 HIV-positive preg-
nant women who failed to be assessed for CD4 count, we
Distribution of regimens used and overall uptake of ARV regimens among women Figure 3
Distribution of regimens used and overall uptake of ARV regimens among women.
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estimate that 6,173 HIV-positive pregnant women who
were eligible failed to be initiated on cART. The MTCT rate
is 7% in mothers with indication for lifelong ART that
receive cART, compared to 26% in HIV-positive pregnant
women with indication for lifelong ART that received a
short-course ARV regimen. [7,8] We therefore estimate
that 1,173 pediatric HIV infections failed to be prevented
because CD4 cell counts were not available for HIV-posi-
tive pregnant women.
Among HIV-positive pregnant women that accessed ARVs
for PMTCT, the proportion of those initiated on cART
increased from 5.3% the first quarter to 7.1% the fourth
quarter (Figure 3). These proportions, although encourag-
ing, remain low compared to global data. UNICEF and
WHO reported that in 2007, among HIV-positive women
that accessed ARV for PMTCT, 9.0% were initiated on life-
long cART. [15] Moreover, a Rwandan study reported a
16.0% proportion of cART among all PMTCT ARV regimes
from health centers and district hospitals. [10] The differ-
ences in proportions initiating cART between our review
and the UNICEF/WHO report and the Rwanda study may
be due to several factors: (1) our review included data
only from PHCs and did not include district hospitals; (2)
unlike Rwanda PMTCT sites, ZPCT-supported sites do not
physically escort HIV-positive pregnant women to ART
clinics; and (3) implementation of efficacious (and com-
plex) ARV regimens were being rolled out in ZPCT-sup-
ported sites during the period of review. [Personal
communication with K. Torpey, 2009]
The increasing trend in uptake of CD4 count assessment,
availability of results at clinics, and cART initiation among
HIV-positive pregnant women as well as the increase in
the overall uptake of ARV regimes are more likely related
to the continuous technical support that ZPCT provided
[Personal communication with K Torpey, 2009]. ZPCT's
technical support consisted of training on the implemen-
tation of the efficacious PMTCT regimen and continuous
mentoring of healthcare providers. For example, the refer-
ral network was reinforced through provision of motor-
bikes to transport blood samples and establishment of a
referral coordinator in each laboratory. Additionally,
patient flow was optimized to reduce client waiting time,
and the capacity of PHCs to initiate cART (whether on site,
through ART mobile clinics, or through referral) was
increased through cART training.
The key to improving implementation of more efficacious
ARV regimens for PMTCT in PHCs lies in building the
capacity to determine CD4 cell count. Looking forward,
several approaches may be used to improve this capacity
in PHCs: (1) providing same-day blood-draw for CD4 cell
enumeration, which requires coordination between ante-
natal and laboratory departments; (2) building reliable
networks for blood-sample transportation and communi-
cation of test results; and (3) strengthening the capacity of
laboratories to perform CD4 cell enumeration with point-
of-care (POC) CD4 count testing. [16-20]
POC CD4 count testing may mitigate the limited capacity
of laboratories and inconsistent sample referral networks.
Using POC CD4 count testing, PHCs can operate with
more flexibility to organize same-day blood-draw for
pregnant women determined to be HIV-positive. How-
ever, the POC CD4 approach has drawbacks: cost per CD4
count test is higher, quality assurance in testing is more
difficult to ensure, and already stretched human resource,
logistics, and supply chain management of PHCs would
be further burdened. [16] While the current approacha
central laboratory and network of PHCs referring sample-
sis not optimal, establishing several CD4 count POC hubs
that cover a smaller number of PHCs may be an alterna-
tive.
To improve implementation of efficacious PMTCT ARV
regimens, PHCs should also maximize initiation of cART
at PMTCT sites: PMTCT providers should be able to assess
eligibility for lifelong ART and initiate cART. This
approach requires intensive training and mentoring and
should be balanced with the already heavy workload of
healthcare providers in antenatal clinic (ANC) settings.
Given the human resource shortages experienced by most
developing countries, increasing the number of providers
at PHCs may not be feasible.
Another option may be to schedule regular mobile ART
clinics visits at antenatal clinics on designated maternal
and child health days.
One major limitation of this review is that only CD4
count (CD4 ≤ 350 cells/mm3 as per the national recom-
mendations) was considered as the criteria to initiate
cART. Although clinical staging is another important crite-
rion, no related data were available. Additionally, analysis
by age was not possible since tools developed for this
review only captured aggregated data.
Another limitation is that reporting on "uptake of ARVs"
refers only to dispensation of ARV drugs and not adher-
ence to the dispensed drugs. Data to ascertain adherence
to dispensed ARV drugs was unavailable. In similar
resource-limited settings, self-reported adherence to ARVs
among pregnant women accessing PMTCT ranged
between 90% and 95%. [21-24] However, a study con-
ducted in Zambia that measured the presence of NVP in
the cord blood of women that accessed PMTCT found an
actual adherence rate of only 68%. [25] In addition, stud-
ies in Kenya and Zambia found that women delivering at
home were two to three times more likely to be non-BMC Public Health 2009, 9:314 http://www.biomedcentral.com/1471-2458/9/314
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adherent. Given that more than 50% of women deliver at
home in Zambia, non-adherence could be a major issue.
[9,11,22] Adherence to complex ARV regimens remains
mostly unknown.
Conclusion
The review revealed that implementation of efficacious
ARV regimes for PMTCT is possible in PHC in resource-
constrained settings. The majority of women identified
eligible for ART were initiated on cART; however, only a
minority of HIV-positive pregnant women were assessed
for CD4 count and had their test results available. Factors
associated with implementation of more efficacious ARV
regimens included timing of blood-draw for CD4 count
and capacity to initiate cART onsite where PMTCT services
were being offered. In order to improve implementation,
multiple obstacles at the health system level should be
addressed. Additional organizational and programmatic
research should examine the causes and potential solu-
tions to bottlenecks. Further research should also be con-
ducted to ascertain adherence rates of HIV-positive
pregnant women to complex ARV regimens.
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